Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5305 plus physician's choice new hormonal agent versus placebo plus new hormonal agent in metastatic castration-sensitive prostate cancer
NL-OMON59416Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing saruparib + physician's choice new hormonal agent with placebo + physician's choice new hormonal agent (2 arms). Primary endpoint: Radiographic progression-free survival. Started Jul 2024; status: active, not recruiting.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59416.